<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Combination therapy with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and etanercept was hypothesized to lead to improved responses in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> were treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> + etanercept; 30 completed at least three therapy cycles </plain></SENT>
<SENT sid="2" pm="."><plain>At 3 months, nine patients had achieved complete response (CR), two had partial response, 10 had marrow CRs, seven had stable disease, two patients had haematological improvement without marrow response and two patients had disease progression </plain></SENT>
<SENT sid="3" pm="."><plain>The overall response rate was 72%; median duration of response was not reached at 2 years </plain></SENT>
<SENT sid="4" pm="."><plain>Marrow response rates and duration were improved with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> + etanercept compared to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> alone </plain></SENT>
</text></document>